What Does Gilead Sciences (GILD) Gain From Its Canada Deal And $45 Million Settlement?

• Gilead Sciences (NasdaqGS:GILD) secured a pan Canadian public reimbursement agreement for LYVDELZI (seladelpar) for primary biliary cholangitis.

• The pact with the pan Canadian Pharmaceutical Alliance supports future public formulary listings that can broaden access across Canadian provinces.

• Gilead agreed to a US$45 million settlement in Texas over allegations of unlawful incentives to healthcare providers.

• The LYVDELZI pan Canadian reimbursement deal, alongside the Texas settlement, deserves to be weighed against the rest of our findings. We have also spotted 2 warning signs worth knowing about at Gilead Sciences.

Consider exploring other healthcare and biotech stocks in related treatment areas through 36 healthcare AI stocks .

Gilead Sciences is a US-based biopharmaceutical group with a US$197.4 billion market cap that focuses on medicines for unmet medical needs across major regions, including the United States and Europe, so adding a liver disease therapy in Canada fits directly into its core therapeutic focus and broad international footprint.

3 things going right for Gilead Sciences that this headline doesn't cover.

What the LYVDELZI deal and Texas settlement really test in the Gilead Sciences story

For Gilead Sciences, the Canada reimbursement agreement backs up the Narrative catalyst that liver and broader immunology programs like seladelpar can become a meaningful third leg alongside HIV and oncology. It pushes the business model deeper into rare liver disease, which lines up with the goal of broadening revenue sources beyond legacy virology. The Texas settlement, by contrast, leans on the risk side. It reinforces execution and compliance concerns in market access that already hang over efforts to convert new therapies into durable cash generation.

See how these catalysts shape Gilead Sciences' path to a $159 fair value .

The clearest early tell will be how quickly Canadian provincial and federal plans start adding LYVDELZI to formularies and defining reimbursement criteria, together with any further disclosure on litigation or compliance costs when Gilead Sciences reports full year 2026 results and updates guidance around the US$3.15b to US$2.75b projected operating loss range.

The question Gilead Sciences investors rarely press hard enough

News moves fast, but the slower question often matters more. That question is what the company's pattern of cash coming in and going out suggests about what the whole business might reasonably be worth next to today's share price. Find out exactly what Gilead Sciences is worth today based on its cash flows .